Susquehanna Fundamental Investments’s Summit Therapeutics SMMT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-19,900	Closed	-$384K	–	979
2025 Q1	$384K	Sell	19,900 -47,478	-70%	-$952K	0.01%	906
2024 Q4	$1.2M	Buy	+67,378	New	+$1.31M	0.02%	652
2024 Q2	$526K	Buy	67,378 +18,501	+38%	+$99.9K	0.01%	683
2024 Q1	$202K	Sell	48,877 -37,335	-43%	-$148K	0.01%	619
2023 Q4	$225K	Hold	86,212	–	–	0.23%	46
2023 Q3	$161K	Hold	86,212	–	–	0.01%	336
2023 Q2	$216K	Sell	86,212 -40,055	-32%	-$73.1K	0.01%	570
2023 Q1	$221K	Buy	126,267 +86,212	+215%	+$235K	0.01%	849
2022 Q4	$170K	Buy	+40,055	New	+$72.9K	﹤0.01%	1088

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Susquehanna Fundamental Investments's SMMT Position: Q2 2025 in Review

Susquehanna Fundamental Investments sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 19,900 shares — an estimated $384K sold.

Susquehanna Fundamental Investments first reported a position in SMMT in Q4 2022 and held it in 9 quarters. The position peaked at $1.2M in Q4 2024. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

Susquehanna Fundamental Investments reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 19,900 Summit Therapeutics shares in Q2 2025, an estimated $384K.
Susquehanna Fundamental Investments first reported a position in Summit Therapeutics in Q4 2022 and held it in 9 quarters.
Susquehanna Fundamental Investments's Summit Therapeutics position peaked at $1.2M in Q4 2024.
238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2025, filed 14 Aug 2025.